BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hou X, Liu R, Huang C, Jiang L, Zhou Y, Chen Q. Cyclophilin A was revealed as a candidate marker for human oral submucous fibrosis by proteomic analysis. Cancer Biomark 2017;20:345-56. [PMID: 28826174 DOI: 10.3233/CBM-170142] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Saso L, Reza A, Ng E, Nguyen K, Lin S, Zhang P, Fantozzi PJ, Armagan G, Romeo U, Cirillo N. A Comprehensive Analysis of the Role of Oxidative Stress in the Pathogenesis and Chemoprevention of Oral Submucous Fibrosis. Antioxidants 2022;11:868. [DOI: 10.3390/antiox11050868] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Qi ZY, Wang F, Yue YY, Guo XW, Guo RM, Li HL, Xu YY. CYPA promotes the progression and metastasis of serous ovarian cancer (SOC) in vitro and in vivo. J Ovarian Res 2019;12:118. [PMID: 31783885 DOI: 10.1186/s13048-019-0593-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
3 Simón Serrano S, Grönberg A, Longato L, Rombouts K, Kuo J, Gregory M, Moss S, Elmér E, Mazza G, Gallay P, Pinzani M, Hansson MJ, Massoumi R. Evaluation of NV556, a Novel Cyclophilin Inhibitor, as a Potential Antifibrotic Compound for Liver Fibrosis. Cells 2019;8:E1409. [PMID: 31717385 DOI: 10.3390/cells8111409] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
4 Shih YH, Wang TH, Shieh TM, Tseng YH. Oral Submucous Fibrosis: A Review on Etiopathogenesis, Diagnosis, and Therapy. Int J Mol Sci 2019;20:E2940. [PMID: 31208114 DOI: 10.3390/ijms20122940] [Cited by in Crossref: 29] [Cited by in F6Publishing: 20] [Article Influence: 9.7] [Reference Citation Analysis]